Vyome Holdings, Inc. (HIND)
Automate Your Wheel Strategy on HIND
With Tiblio's Option Bot, you can configure your own wheel strategy including HIND - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company
Published: December 22, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass.--(BUSINESS WIRE)--LICH LOI with Remus.
Read More
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing
Published: November 18, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings Third Quarter 2025 Earnings Release.
Read More
Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity
Published: September 17, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, presented results from its preclinical studies investigating VT-1908 (the first topical formulation of mycophenolate) for treating uveitis at the recent Annual Meeting of the American Society for Pharmacology and Experimental Therapeutics (1). Uveitis is the inflammation of a part of the eye, and is implicated in 30,000 new cases of legal blindness annually, in the United States.
Read More
About Vyome Holdings, Inc. (HIND)
- IPO Date 2016-10-06
- Website https://www.vyometx.com
- Industry Biotechnology
- CEO Venkateswarlu Nelabhotla
- Employees 18